#Sustainability #Sweden #Stockholm #Annual Report #Sobi

Sobi Unveils 2024 Annual and Sustainability Report

On March 31, 2025, Swedish Orphan Biovitrum AB (publ), commonly known as Sobi®, released its much-anticipated Annual and Sustainability Report for 2024. The document highlights the significant strides made by the company in the past year, particularly in the realm of innovative treatments for individuals suffering from rare diseases. Sobi's commitment to sustainability and patient accessibility takes a central role in the report, outlining future trajectories aimed at enhancing healthcare worldwide.

Key Highlights of the Report

The report serves a dual purpose: it not only acts as an annual financial overview but also complies with sustainability regulations following the Swedish Annual Accounts Act, structured around GRI Standards 2021, and inspired by the European Sustainability Reporting Standards (ESRS). This blend of financial and ethical accountability presents Sobi as a responsible corporate entity that prioritizes patient welfare and environmental stewardship.

Among the transformative initiatives mentioned, Sobi is focusing on identifying and unlocking potential breakthroughs in the treatment of rare diseases. The aspiration is not only to innovate but also to ensure that all eligible patients can access the necessary therapeutic options. This reflects Sobi’s strong commitment to improving patient outcomes through enhanced medication access.

Sustainability Efforts

One noteworthy aspect of the report is Sobi's alignment with global sustainability directives. The document includes the Task Force on Climate-related Financial Disclosures (TCFD) report, along with insights relating to the EU Taxonomy disclosures. These components indicate Sobi's dedication to managing its environmental impact and ensuring sustainability in its operations.

Transitioning towards compliance with the Corporate Sustainability Reporting Directive (CSRD) has also been listed as a key objective. In 2024, Sobi implemented various structural elements of ESRS, reflecting its adaptive approach to new sustainability mandates. By adjusting the report's disposition to meet these requirements, Sobi showcases a readiness to engage proactively with evolving environmental standards.

Financial Overview

In the realm of financial performance, Sobi reported an impressive revenue of SEK 26 billion in 2024. This robust figure evidences the company's healthy business model while underscoring the efficacy of the pharmaceutical solutions they deliver to patients worldwide. With approximately 1,800 employees operating across various regions—including Europe, North America, the Middle East, Asia, and Australia—Sobi is positioned as a significant player in the global biopharmaceutical arena.

Future Directions

As the company looks to the future, Sobi is dedicated to continuous innovation in hematology, immunology, and specialty care. The 2024 Annual and Sustainability Report not only shares Sobi’s achievements but also heralds a promising path ahead, keeping rare disease treatment at the forefront of its mission.

The report is publicly accessible via Sobi’s official website, sobi.com, where stakeholders and the general public can delve into the specifics of the company's achievements and sustainability commitments. For the Swedish Annual Report, an electronic format compliant with the European Single Electronic Format (ESEF) is available, ensuring comprehensive transparency and accessibility.

In conclusion, the publication of Sobi’s Annual and Sustainability Report for 2024 stands as a testament to the company’s enduring commitment to making a meaningful impact in the lives of patients with rare diseases while championing sustainability and responsible corporate citizenship.